“Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer” has been added to your cart. View cart
Article: PP48 Validation of first trimester non-invasive fetal RhD genotyping for targeted antenatal anti-D prophylaxis
PP48 Validation of first trimester non-invasive fetal RhD genotyping for targeted antenatal anti-D prophylaxis
Reviews
There are no reviews yet.
Be the first to review “Article: PP48 Validation of first trimester non-invasive fetal RhD genotyping for targeted antenatal anti-D prophylaxis” Cancel reply
Reviews
There are no reviews yet.